Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    A new site revision tag (Revision: v3.4.2) is added, and an older Revision: v3.4.1 tag along with a government funding lapse notice has been removed. These changes are cosmetic and do not affect trial details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T10:59:27.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A new site-wide notice states that information may not be up to date due to a lapse in government funding and directs users to update status at opm.gov. The page revision has been updated from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T06:32:51.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The changes are minor UI/text updates: a 'Show glossary' addition, capitalization adjustments for QC criteria labels, a 'No FEAR Act Data' label, and a new 'Revision: v3.4.0' label replacing the previous 'v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T04:32:59.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no visible changes to the study content or page layout were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:22:12.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    A consolidated Locations section now lists California, Illinois, Indiana, and Virginia, replacing the former separate California Locations, Illinois Locations, Indiana Locations, and Virginia Locations subsections; the HHS Vulnerability Disclosure link was removed.
    Difference
    0.5%
    Check dated 2025-12-23T10:14:42.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    Minor site-wide update applied: Revision v3.3.2 replaces v3.3.1; no changes to the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T17:52:37.000Z thumbnail image

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.